Parenteral medication, administered intramuscularly in doses of 2 to 5 mg, is utilized for prompt control of the acutely agitated schizophrenic patient with moderately severe to very severe symptoms. The optimal response in such patients is usually obtained with more gradual dosage adjustments and at lower dosage levels. Debilitated or geriatric patients, as well as those with a history of adverse reactions to antipsychotic drugs, may require less HALDOL (haloperidol). To determine the initial dosage, consideration should be given to the patient's age, severity of illness, previous response to other antipsychotic drugs, and any concomitant medication or disease state. Dosage adjustments, either upward or downward, should be carried out as rapidly as practicable to achieve optimum therapeutic control. As with all drugs used to treat schizophrenia, dosage should be individualized according to the needs and response of each patient. There is considerable variation from patient to patient in the amount of medication required for treatment. HALDOL is indicated for the control of tics and vocal utterances of Tourette's disorder. HALDOL (haloperidol) is indicated for use in the treatment of schizophrenia. Common adverse reactions include hypotension, constipation, xerostomia, akathisia, dystonia, extrapyramidal disease, somnolence, and blurred vision.Īdult Indications and Dosage FDA-Labeled Indications and Dosage (Adult) Indications There is a Black Box Warning for this drug as shown here. Haloperidol (injection) is an antipsychotic agent that is FDA approved for the treatment of schizophrenia. HALDOL Injection is not approved for the treatment of patients with dementia-related psychosis The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.

Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.

Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Increased Mortality in Elderly Patients with Dementia-Related PsychosisĮlderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

Haloperidol antidote